REFERENCES

1. McKenna DJ, Errington R, Pors K. Current challenges and opportunities in treating hypoxic prostate tumors. J Cancer Metastasis Treat 2018;4:11.

2. Vaupel P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007;9:1221-35.

3. Vaupel P, Kelleher DK. Blood flow and oxygenation status of prostate cancers. Adv Exp Med Biol 2013;765:299-305.

4. McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol 2014;87:20130676.

5. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39.

6. Vaupel P, Mayer A, Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004;381:335-54.

7. Vaupel P, Multhoff G. A metabolic immune checkpoint: adenosine in tumor microenvironment. Front Immunol 2016;7:332.

8. Vaupel P, Mayer A. Tumor oxygenation status: facts and fallacies. Adv Exp Med Biol 2017;977:91-9.

9. Grote J, Süsskind R, Vaupel P. Oxygen diffusivity in tumor tissue (DS-carcinosarcoma) under temperature conditions within the range of 20-40°C. Pflügers Arch 1977;372:37-42.

10. Thews G, Vaupel P. Autonomic Functions in Human Physiology. Berlin, Heidelberg, New York, Tokyo: Springer; 1985.